早期和转移性三阴性乳腺癌的治疗管理：综述。
The management of early-stage and metastatic triple-negative breast cancer: a review.
机构信息
Division of Hematology-Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA.
出版信息
Hematol Oncol Clin North Am. 2013 Aug;27(4):737-49, viii. doi: 10.1016/j.hoc.2013.05.003. Epub 2013 Jun 18.
Abstract
Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are several biologically distinct subtypes within TNBC. Although the incidence of BRCA mutations across all subsets of breast cancer is low, BRCA mutations are more common among those with TNBC and may have therapeutic implications. The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC.
摘要
三阴性乳腺癌（TNBC）定义为缺乏雌激素受体、孕激素受体和 HER2 的表达，约占新发乳腺癌的 15%，并且在转移性疾病患者中更为常见。TNBC 中有几种生物学上明显不同的亚型。尽管所有乳腺癌亚组的 BRCA 突变发生率都较低，但 TNBC 中 BRCA 突变更为常见，并且可能具有治疗意义。指导早期 TNBC 和非 TNBC 化疗和放疗使用的一般原则没有明显差异。
相似文献
1
The management of early-stage and metastatic triple-negative breast cancer: a review.早期和转移性三阴性乳腺癌的治疗管理：综述。
Hematol Oncol Clin North Am. 2013 Aug;27(4):737-49, viii. doi: 10.1016/j.hoc.2013.05.003. Epub 2013 Jun 18.
2
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.猫乳腺基底样腺癌：一种具有基底样亚型的人类三阴性乳腺癌（TNBC）的潜在模型。
BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.
3
Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.加纳女性的三阴性乳腺癌：科勒布教学医院的经验
Breast J. 2015 Nov-Dec;21(6):627-33. doi: 10.1111/tbj.12527.
4
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.三阴性乳腺癌治疗方法的进展。
Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.
5
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.早期三阴性乳腺癌治疗进展。
Curr Treat Options Oncol. 2018 Apr 14;19(5):22. doi: 10.1007/s11864-018-0539-8.
6
Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?三阴性乳腺癌（TNBC）与非三阴性乳腺癌的预后比较：各分期的生存率是否存在差异？
World J Surg. 2016 Jun;40(6):1362-72. doi: 10.1007/s00268-016-3422-4.
7
Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?三阴性乳腺癌（TNBC）亚型是否会影响局部区域治疗的决策？
Am Soc Clin Oncol Educ Book. 2014:e32-6. doi: 10.14694/EdBook_AM.2014.34.e32.
8
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.三阴性乳腺癌的演变：从生物学到新型疗法
Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.1200/EDBK_159135.
9
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.在早发性散发性乳腺癌遗传咨询队列中，有限的家族结构和三阴性乳腺癌（TNBC）亚型作为BRCA突变的预测因素。
Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.
10
Characteristics of male triple negative breast cancer: A population-based study.男性三阴性乳腺癌的特征：一项基于人群的研究。
Breast J. 2020 Sep;26(9):1748-1755. doi: 10.1111/tbj.14023. Epub 2020 Aug 27.
引用本文的文献
1
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence.转移性三阴性乳腺癌患者的二线治疗选择：临床证据综述
Target Oncol. 2025 Mar;20(2):191-213. doi: 10.1007/s11523-024-01125-1. Epub 2025 Jan 13.
2
Antibody-drug conjugates for breast cancer: a bibliometric study and clinical trial analysis.用于乳腺癌的抗体药物偶联物：一项文献计量学研究与临床试验分析
Discov Oncol. 2024 Aug 2;15(1):329. doi: 10.1007/s12672-024-01192-w.
3
Early detection of breast cancer through the diagnosis of Nipple Aspirate Fluid (NAF).通过乳头抽吸液（NAF）诊断实现乳腺癌的早期检测。
Clin Proteomics. 2024 Jun 28;21(1):45. doi: 10.1186/s12014-024-09495-4.
4
Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.转移性三阴性乳腺癌患者的治疗模式和临床结局：基于日本理赔数据库的大规模数据分析。
Breast Cancer Res Treat. 2024 Jul;206(1):91-103. doi: 10.1007/s10549-024-07273-2. Epub 2024 May 5.
5
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.转移性三阴性乳腺癌及其他实体瘤患者Sacituzumab Govitecan 的群体药代动力学。
Clin Pharmacokinet. 2024 May;63(5):669-681. doi: 10.1007/s40262-024-01366-3. Epub 2024 Apr 5.
6
Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.细胞形态能最佳预测不同转移潜能的多种三阴性乳腺癌细胞系在体内的致瘤性和转移情况。
Breast Cancer Res. 2024 Mar 11;26(1):43. doi: 10.1186/s13058-024-01796-8.
7
Cost-effectiveness analysis of tumor-infiltrating lymphocytes biomarkers guiding chemotherapy de-escalation in early triple-negative breast cancer.肿瘤浸润淋巴细胞生物标志物指导早期三阴性乳腺癌化疗降阶梯的成本效益分析。
Cancer Med. 2023 Nov;12(22):21001-21012. doi: 10.1002/cam4.6656. Epub 2023 Nov 14.
8
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study.多西他赛和达沙替尼对三阴性乳腺癌的体外和体内作用：一项研究
Cureus. 2023 Aug 15;15(8):e43534. doi: 10.7759/cureus.43534. eCollection 2023 Aug.
9
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.转移性三阴性乳腺癌的奥地利更新治疗算法。
Wien Klin Wochenschr. 2024 Jun;136(11-12):347-361. doi: 10.1007/s00508-023-02254-9. Epub 2023 Sep 8.
10
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.三阴性乳腺癌的治疗选择与局限性：未来展望
Pharmaceutics. 2023 Jun 23;15(7):1796. doi: 10.3390/pharmaceutics15071796.
本文引用的文献
1
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
2
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.联合 PI3K/mTOR 和 MEK 抑制在忠实的鼠类癌症模型中提供广泛的抗肿瘤活性。
Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7.
3
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.TBCRC 001：西妥昔单抗联合卡铂治疗 IV 期三阴性乳腺癌的随机 II 期研究。
J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.
4
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.用组蛋白去乙酰化酶抑制剂 panobinostat 靶向三阴性乳腺癌细胞。
Breast Cancer Res. 2012 May 21;14(3):R79. doi: 10.1186/bcr3192.
5
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.针对三阴性乳腺癌中靶向 MEK 抑制的激酶组的动态重编程。
Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053.
6
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.针对 p53 缺陷型三阴性乳腺癌中的 Chk1 进行靶向治疗在人源化小鼠肿瘤模型中具有治疗益处。
J Clin Invest. 2012 Apr;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26.
7
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.多模态治疗治疗 T1a/T1bN0 三阴性乳腺癌患者的预后良好。
Cancer. 2012 Oct 15;118(20):4944-52. doi: 10.1002/cncr.27480. Epub 2012 Mar 5.
8
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.NCIC.CTG MA.5 随机试验中内在亚型对辅助蒽环类药物替代的反应性。
Clin Cancer Res. 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20.
9
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.新辅助化疗联合贝伐珠单抗治疗人表皮生长因子受体 2 阴性乳腺癌。
N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.
10
Triple-negative breast cancer is not a contraindication for breast conservation.三阴性乳腺癌不是保乳手术的禁忌证。
Ann Surg Oncol. 2011 Oct;18(11):3164-73. doi: 10.1245/s10434-011-1920-z. Epub 2011 Sep 27.
Zotero 插件